Tolerance and efficacy of intranasal administration of recombinant beta serine interferon in healthy adults.
Tolerance and efficacy of intranasal administration of recombinant beta serine interferon in healthy adults.
复制标题
健康成人鼻内施用重组β丝氨酸干扰素的耐受性和功效。
DOI：
10.1093/infdis/158.1.166
复制
发表时间：
1988
期刊：
影响因子：
--
通讯作者：
Hayden,FG
中科院分区：
文献类型：
--
作者：
Sperber,SJ;Levine,PA;Innes,DJ;Mills,SE;Hayden,FG
我们进行了两项研究，以确定重组干扰素丝氨酸干扰素(β-βSer)对实验性鼻病毒感染的剂量相关耐受性和疗效。在耐受性研究中，120名健康成年人每天鼻腔喷洒重组干扰素-β血清安慰剂，持续25天。没有发现鼻部症状的差异。鼻镜检查发现高剂量组(38%)比低剂量组(12.5%)或安慰剂组(12.5%)有更多的粘膜出血部位。在鼻活检标本中，高剂量组(54%)比低剂量组(17%)或安慰剂组(17%)有更多的上皮下淋巴细胞。在疗效研究中，34名志愿者每天接受干扰素滴鼻，从挑战前36小时开始，持续3天。感染数量和病毒脱落天数并未减少，但高剂量(25%)的感冒发生率低于低剂量(55%)或安慰剂()接受者。高剂量组鼻腔粘液重量(平均每5天±SDg；5±4)低于安慰剂组(31±37)。因此，重组干扰素-β血清可能具有比先前测试的α干扰素更有利的治疗比率。
We performed two studies to determine the dose-related tolerance and the efficacy of recombinant βserineinterferon (rIFN-βser) in experimental rhinovirus infection. In the tolerance study, 120 healthy adults received intranasal sprays of rIFN-βseror placebo daily for 25 d. No differences in nasal symptoms were found. Rhinoscopy detected more mucosal bleeding sites in high-dose (38%) versus low-dose (12.5%) or placebo (12.5%) recipients. There were more subepithelial lymphocytes in nasal biopsy specimens in the high-dose (54%) than the low-dose (17%) or placebo (17%) groups. In the efficacy study, 34 volunteers received daily nasal drops of IFN, beginning 36 h before challenge and for three days afterwards. The numbers of infections and days of shedding of virus were not reduced, but colds occurred less often in the high-dose (25%) than in the low-dose (55%) or placebo (64%) recipients. Nasal mucus weights were lower in the high-dose (mean ± SD g per five days; 5 ± 4) than placebo (31 ± 37) recipients. Thus, rIFN-βsermay have a more favorable therapeutic ratio than do previously tested α interferons.